Autopsy report · NCT04687800

Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

“Inability to enroll due to lack of access to the Ambulatory Surgery Center.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 11 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Cathleen McCabe MD

Sponsor type

University, hospital or other

Conditions

Cataract

Interventions

Dextenza 0.4mg intracanalicular Insert; Durezol 0.05% Ophthalmic Emulsion

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Wellness Initiative at New York University
  “Due to inability to enroll patients” (73% match in meaning)
• Comparison of Three Approaches of Electrode Placement to Detect Changes in Motor Evoked Potentials During Spine Surgery
  “Unable to enroll patients.” (72% match in meaning)
• Efficacy of a Home-Based Exercise Program for Heart Failure
  “Lack of enrollment. Difficult to obtain Physician approval.” (70% match in meaning)
• Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
  “Unable to enroll patients, no longer at institution.” (68% match in meaning)
• Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use
  “Insufficient patient enrollment.” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.